C3orf62 and non-small cell lung carcinoma: We found that the IC50 values of three drugs, including Doramapimod_1042, SB505124_1194 and Ribociclib_1632, were significantly higher in circulating MAPS-high group than that in MAPS-low group (Fig. 6A–C), suggesting that NSCLC patients with high circulating MAPS were more resistant to these chemotherapy drugs.